What is the recommended workup and treatment plan for a patient with suspected mast cell disorder?

Workup and Treatment for Suspected Mast Cell Disorder

For a patient with suspected mast cell disorder, begin with serum tryptase measurement and proceed to bone marrow biopsy with KIT D816V mutation testing if systemic mastocytosis is suspected, while simultaneously initiating H1 and H2 antihistamine therapy for symptom control. 1

Initial Diagnostic Workup

Step 1: Clinical Assessment and Initial Laboratory Testing

Start with these specific evaluations:

• Serum tryptase level - This is your first-line screening test 1
• CBC with differential - Look specifically for monocytosis, eosinophilia, or dysplasia 1
• Comprehensive metabolic panel including uric acid, LDH, and liver function tests 1
• Document specific symptoms: Look for episodic flushing, pruritus, urticaria, angioedema, abdominal cramping, diarrhea, nausea, headache, hypotension, tachycardia, or anaphylaxis 1
• Examine for skin lesions (mastocytosis in the skin) and assess spleen/liver size 1

Step 2: Determine Disease Category

The diagnostic pathway diverges based on presentation 1:

If mast cell activation symptoms OR adult-onset skin lesions OR elevated tryptase:

• Proceed to bone marrow biopsy or biopsy of organ with suspected involvement 1
• Obtain molecular testing for KIT D816V mutation (if needed, additional KIT gene sequencing) 1
• Perform mast cell immunophenotyping using flow cytometry (CD117, CD25, CD2; CD30 optional) and/or immunohistochemistry (CD117, CD25, tryptase) 1
• If eosinophilia present, screen for FIP1L1-PDGFRA 1

Diagnosis requires:

• Systemic mastocytosis: 1 major + 1 minor criterion OR ≥3 minor criteria based on 2017 WHO criteria 1, 2
• Primary MCAS: Specific criteria including episodic symptoms in ≥2 organ systems, objective evidence of mast cell mediator release, and response to mast cell-directed therapy 3, 4

Step 3: Rule Out Secondary Causes

Before diagnosing primary MCAS, exclude 1, 3:

• Secondary MCAS from allergies, drugs, infections
• Medication-induced angioedema (stop suspected medication, assess response over 1-2 months) 5
• Hereditary alpha-tryptasemia (TPSAB1 gene duplications/triplications) 1

Critical caveat: Serum tryptase may be <20 ng/mL or only transiently elevated in mast cell disorders 1. A normal baseline tryptase does NOT exclude the diagnosis 6.

Treatment Algorithm

Immediate Management for Acute Episodes

For anaphylaxis or severe mast cell activation:

• Epinephrine IM immediately - 500 mcg (0.5 mL of 1:1000) for adults 7
• IV adrenaline 50 mcg (0.5 mL of 1:10,000) if IV access available, titrate to response 7
• Fluid resuscitation with 0.9% saline or lactated Ringer's at high rate 7
• Chlorphenamine 10 mg IV (adult dose) 7
• Hydrocortisone 200 mg IV (adult dose) 7
• Draw serum tryptase within 30-120 minutes of symptom onset, then at 24 hours for baseline comparison 7, 1

Chronic Symptom Management - Stepwise Approach

First-line therapy 3, 8, 9:

• H1 antihistamines: Start with second-generation (cetirizine, loratadine, fexofenadine). Escalate to 4-fold standard dose if inadequate response 5, 3
• H2 antihistamines: Add famotidine or ranitidine for abdominal symptoms or vascular symptoms 3

Second-line additions 3, 8:

• Montelukast (leukotriene receptor antagonist) - particularly effective for dermatologic symptoms when combined with H1 antihistamines 3
• Oral cromolyn sodium 200 mg four times daily (before meals and bedtime) - primarily for gastrointestinal symptoms. Counsel patients that onset may take ≥1 month 3, 8

Third-line options 3, 8:

• Aspirin for refractory flushing/hypotensive episodes related to PGD2 (introduce in controlled setting due to risk of triggering degranulation) 3
• Omalizumab for antihistamine-resistant cases - expensive but effective for preventing anaphylaxis and emergency visits 3, 8

For osteopenia/osteoporosis (common in systemic mastocytosis) 1:

• Supplemental calcium and vitamin D
• Bisphosphonates (continue antihistamines concurrently) - improves vertebral bone mineral density more than femoral 1
• Denosumab as second-line for bisphosphonate-refractory bone pain or renal insufficiency 1
• PEG-interferon-alfa for refractory bone pain despite bisphosphonates 1

Special Situations

Perioperative management 1:

• Multidisciplinary coordination with surgery, anesthesia, perioperative teams is mandatory 1
• Pre-anesthetic prophylaxis: Benzodiazepines, H1 and H2 blockers, possibly corticosteroids 1
• Safer agents: Propofol, sevoflurane/isoflurane, fentanyl/remifentanil, lidocaine, bupivacaine 1
• Avoid: Atracurium, mivacurium, succinylcholine; use rocuronium/vecuronium instead 1
• Avoid temperature extremes and unnecessary trauma 1

Pregnancy 1:

• Requires high-risk obstetrics, anesthesia, and allergy team involvement 1
• SM does not appear to affect fertility 1
• Insufficient evidence exists regarding increased adverse maternal/fetal outcomes 1

Critical Pitfalls to Avoid

1. Do not rely solely on baseline tryptase - It can be normal in MCAS and only transiently elevated during episodes 1, 6

2. Do not withhold analgesics in surgical patients with SM - pain itself triggers mast cell activation 1

3. Do not diagnose MCAS without objective evidence of mast cell mediator release (acute tryptase elevation or urinary metabolites) 4, 6

4. Do not skip bone marrow evaluation in adults with systemic symptoms and elevated tryptase - clonal mast cell disorders require different management 1, 2

5. Refer to specialized centers - The NCCN explicitly recommends referral to centers with expertise in mast cell disorders for optimal multidisciplinary management 1